Center for Genetic Epidemiology, Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, California.
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Genes Chromosomes Cancer. 2019 Oct;58(10):723-730. doi: 10.1002/gcc.22765. Epub 2019 May 27.
High hyperdiploidy (HD) is the most common cytogenetic subtype of childhood acute lymphoblastic leukemia (ALL), and a higher incidence of HD has been reported in ALL patients with congenital cancer syndromes. We assessed the frequency of predisposing germline mutations in 57 HD-ALL patients from the California Childhood Leukemia Study via targeted sequencing of cancer-relevant genes. Three out of 57 patients (5.3%) harbored confirmed germline mutations that were likely causal, in NBN, ETV6, and FLT3, with an additional six patients (10.5%) harboring putative predisposing mutations that were rare in unselected individuals (<0.01% allele frequency in the Exome Aggregation Consortium, ExAC) and predicted functional (scaled CADD score ≥ 20) in known or potential ALL predisposition genes (SH2B3, CREBBP, PMS2, MLL, ABL1, and MYH9). Three additional patients carried rare and predicted damaging germline mutations in GAB2, a known activator of the ERK/MAPK and PI3K/AKT pathways and binding partner of PTPN11-encoded SHP2. The frequency of rare and predicted functional germline GAB2 mutations was significantly higher in our patients (2.6%) than in ExAC (0.28%, P = 4.4 × 10 ), an observation that was replicated in ALL patients from the TARGET project (P = .034). We cloned patient GAB2 mutations and expressed mutant proteins in HEK293 cells and found that frameshift mutation P621fs led to reduced SHP2 binding and ERK1/2 phosphorylation but significantly increased AKT phosphorylation, suggesting possible RAS-independent leukemogenic effects. Our results support a significant contribution of rare, high penetrance germline mutations to HD-ALL etiology, and pinpoint GAB2 as a putative novel ALL predisposition gene.
高倍体性(HD)是儿童急性淋巴细胞白血病(ALL)中最常见的细胞遗传学亚型,在伴有先天性癌症综合征的 ALL 患者中,HD 的发病率更高。我们通过对癌症相关基因的靶向测序,对来自加利福尼亚儿童白血病研究的 57 例 HD-ALL 患者进行了易感性种系突变的评估。57 例患者中有 3 例(5.3%)存在 NBN、ETV6 和 FLT3 中确认的种系突变,这些突变可能是致病的,另外 6 例(10.5%)存在罕见的种系突变,这些突变在未选择的个体中很少见(在 Exome Aggregation Consortium,ExAC 中的等位基因频率<0.01%),并且在已知或潜在的 ALL 易感性基因(SH2B3、CREBBP、PMS2、MLL、ABL1 和 MYH9)中预测功能( scaled CADD score≥20)。另外 3 例患者携带 GAB2 中罕见且预测具有破坏性的种系突变,GAB2 是 ERK/MAPK 和 PI3K/AKT 途径的已知激活剂,也是编码 SHP2 的 PTPN11 的结合伙伴。我们的患者中罕见且预测具有功能的种系 GAB2 突变的频率明显高于 ExAC(2.6%比 0.28%,P=4.4×10-6),这一观察结果在 TARGET 项目的 ALL 患者中得到了复制(P=0.034)。我们克隆了患者的 GAB2 突变,并在 HEK293 细胞中表达突变蛋白,发现移码突变 P621fs 导致 SHP2 结合减少和 ERK1/2 磷酸化,但显著增加 AKT 磷酸化,提示可能存在 RAS 非依赖性白血病效应。我们的结果支持罕见的、高外显率种系突变对 HD-ALL 病因学的重要贡献,并指出 GAB2 是一个潜在的新的 ALL 易感性基因。